EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG) Files An 8-K Other Events
Item 8.01.

On November 22, 2019, EyeGate Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company has received select topline data, specifically the primary endpoint, demonstrating superiority over standard-of-care in the Company’s corneal wound repair pivotal study using the Ocular Bandage Gel, or OBG, eye drop.

The press release is filed as Exhibit 99.1 and investors should read the press release in its entirety, including the cautionary statements regarding forward looking statements therein.

 

(d)

Exhibits.

The Company hereby files the following exhibit:

99.1	Press Release of the Company, dated as of November 22, 2019.

EYEGATE PHARMACEUTICALS INC Exhibit
EX-99.1 2 tm1923677d1_ex991.htm EXHIBIT 99.1 Exhibit 99.1    EyeGate Pharma Hits Primary Endpoint in PRK Pivotal Study   WALTHAM,…
To view the full exhibit click here

About EYEGATE PHARMACEUTICALS, INC. (NASDAQ:EYEG)

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.